M&A / Deals Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Pharmaceutical Business ReviewThe value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments.Rare DiseaseRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaceutical Business Review The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. Rare Disease Read full story Post navigation Previous: ASCO26: AZ triplet makes waves in frontline liver cancerNext: ASCO26: Symptom-tracking app helps advanced cancer patients Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026